Placebo News and Research

RSS

FDA accepts Sucampo's sNDA for Lubiprostone for the treatment of irritable bowel syndrome

Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).

18 Sep 2007

$Once a year osteoporosis jab reduces fractures and saves lives$

Once a year osteoporosis jab reduces fractures and saves lives

A once a year injection of an osteoporosis drug has been found to reduce the number of new hip fractures for older people and also saves lives.

18 Sep 2007

Goals in Action program shows promise in helping struggling students

What can colleges and universities do to help their low-performing students set and attain higher academic goals while transitioning successfully to campus life?

18 Sep 2007

Smoking-cessation may be in the genes

Whether a smoking-cessation drug will enable you to quit smoking may depend on your genes, according to new genotyping research from the Centre for Addiction and Mental Health (CAMH).

18 Sep 2007

Palate implants for obstructive sleep apnea - study

When loud snoring is interrupted by frequent episodes of obstructed breathing, it is known as obstructive sleep apnea (OSA). As many as 12 million people in the U.S. suffer from this condition, which can require surgical intervention when lifestyle changes and other treatment options fail.

18 Sep 2007

Evista (raloxifene hydrochloride) approved for breast cancer

The U.S. Food and Drug Administration today approved Evista (raloxifene hydrochloride) for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.

17 Sep 2007

Breast cancer drug tamoxifen helps treat symptoms of bipolar disease

Government researchers in the United States have found that the breast cancer drug tamoxifen helped treat the manic symptoms of bipolar disease.

13 Sep 2007

Shrinkage of prostate led to overestimation of cancer risk in finasteride trial

Reanalysis of data from the first long-term randomized trial of a chemopreventive agent for prostate cancer shows that the excess prevalence of high-grade prostate cancer in the drug-treated group may be attributable to shrinkage of the prostate at the time of biopsy.

13 Sep 2007

Tamoxifen for bipolar disorder

The medication tamoxifen, best known as a treatment for breast cancer, dramatically reduces symptoms of the manic phase of bipolar disorder more quickly than many standard medications for the mental illness, a new study shows.

13 Sep 2007

Amino acid, N-acetyl cysteine may curb addiction of pathological gamblers

University of Minnesota researchers have discovered that a common amino acid, available as a health food supplement, may help curb pathological gamblers' addiction.

12 Sep 2007

Long-term use of rosiglitazone (Avandia) increases heart attack risk by more than 40 percent

An analysis of four studies involving more than 14,000 patients found that long-term use of the diabetes drug rosiglitazone (Avandia) increased the risk of heart attack by 42 percent and doubled the risk of heart failure, according to a new report from researchers at Wake Forest University School of Medicine and colleagues.

12 Sep 2007

GlaxoSmithKline responds to Journal of the American Medical Association articles

GlaxoSmithKline believes that conclusions drawn from the most recent meta-analyses published by Drs. Nissen et. al. and Furberg et. al. in the Journal of the American Medical Association do not confirm a difference in the safety profile of Avandia (rosiglitazone) and Actos (pioglitazone).

12 Sep 2007

Generic prostate drug finasteride helps find high-risk cancers early

Men now have another good reason to consider taking finasteride, a well-known generic drug that shrinks an enlarged prostate and reduces the risk of getting prostate cancer by 25 percent.

12 Sep 2007

Finasteride unlikely to induce high grade prostate cancers

An increase in high-grade prostate cancer among men taking the drug finasteride is likely caused by an increased detection of cancers, and not by the development of more high-grade cancers, according to two studies published online September 11 in the Journal of the National Cancer Institute.

12 Sep 2007